INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Latuda (Sunovion)
- INDICATIONS: Schizophrenia, depressive epidodes associated with bipolar I disorder
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: 18 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Amphetamines, CNS depressants, Dasatinib, Deferasirox, Diltiazem, Disopyramide, Dopamine, Dopamine agonists, Droperidol, Efavirenz, Epinephrine, Hydroxyzine, Itraconazole, Ketoconazole, Levomepromazine, Lithium, MAO inhibitors, Methylphenidate, Metoclopramide, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Pimozide, Procainamide, Quinagolide, Quinidine, Rifampin, Strong CYP3A4 inducers or inhibitors, Tetrabenazine, Tocilizumab, Viloxazine
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of lurasidone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/22/2024
